Report

Preview Analysis

Request Insights

Inflation and Looming Recession to Haunt Businesses:

In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022. Purchasing power in the country is expected to fell nearly by 2.5%.
On the other hand, European countries to see the worst coming in the form of energy crisis especially in upcoming winters!! Right after COVID-19, inflation has started gripping the economies across the globe. Higher than anticipated inflation, especially in western world had raised concerns for national banks and financial institutions to control the economic loss and safeguard the interest of the businesses. Increased interest rates, strong USD inflated oil prices, looming prices for gas and energy resources due to Ukraine-Russia conflict, China economic slowdown (~4% in 2022) disrupting the production and global supply chain and other factors would impact each industry negatively.

In The News

June 02, 2021: Sun Pharmaceutical Industries Limited entered a collaborative agreement with Ferring Pharmaceuticals Pvt. Ltd. (Ferring), a Switzerland-based biopharmaceuticals MNC, to commercialize a room temperature stable formulation of obstetric drug, CARITEC (Carbetocin RTS) in India.
April 28, 2021: Merck Sharp & Dohme Corp. announced the complete acquisition of Pandion Therapeutics. After this acquisition, Pandion Therapeutics became a wholly-owned subsidiary of Merck Sharp & Dohme Corp.

Key Questions Answered in the Report

1) What are the major factors driving the growth of the carvedilol drug market?

Ans: The growing prevalence heart diseases and hypertension is estimated to boost the market growth.

2) What would be the CAGR of carvedilol drug market over the forecast period?

Ans: The market is anticipated to attain a significant CAGR over the forecast period, i.e., 2022 – 2031.

5) Who are the major players dominating the carvedilol drug market?

Ans: The major players in the market are Novartis AG, Sanofi-aventis Groupe, Abbott Laboratories, Merck & Co., Inc., Siemens Healthcare GmbH, Amgen Inc., Daiichi Sankyo Company, Limited, and Pfizer Inc.

6) How are the company profiles selected?

Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

7) What are the segments in the carvedilol drug market?

Ans: The market is segmented by product, application, distribution channel, and by region.

8) Which segment captures the largest market size in application segment in the carvedilol drug market?

Ans: The congestive heart failure (CHF) segment is anticipated to hold largest market size over the forecast period and display significant growth opportunities.

8) What are the challenges affecting the market growth?

Ans: Carvedilol has some side effects, such as, dizziness, and tiredness, and is unsafe for consumption during pregnancy, which is estimated to hamper the market growth.

8) Which region will provide more business opportunities for growth of the carvedilol drug market in future?

Ans: The North America region is anticipated to provide more business opportunities over the forecast period owing to the increasing prevalence of heart failure in the region.

Healthcare & Pharmaceutical